Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01204762 · ClinicalTrials.gov registry record · Phase 2
Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 197
- Enrollment target
NCT01204762 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 197 participants.
The verdict
NCT01204762, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 197 participants
- Enrollment target
Study Summary
At least 1 dose of pegIFNλ will be identified which is safe, well tolerated, and efficacious for the treatment of chronic hepatitis B virus infection (CHB) Amendment 7, Part B Sub Study: The primary purpose of this amendment is to obtain preliminary data on the safety of pegylated interferon Lambda (Lambda) when administered in combination with Entecavir(ETV) to patients with hepatitis E antigen-positive (HBeAg-positive) chronic hepatitis B(CHB) infection employing a sequential therapy approach
Interventions
- DRUG Entecavir
- DRUG pegIFN
- DRUG pegIFNα-2a
- DRUG PegIFN lambda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 197 participants |
| Start Date | 2010-11 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01204762
The ClinicalTrials.gov registry entry for NCT01204762 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 197 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Entecavir is the first listed.
NCT01204762 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01204762 about?
NCT01204762 is a clinical study titled "Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen". At least 1 dose of pegIFNλ will be identified which is safe, well tolerated, and efficacious for the treatment of chronic hepatitis B virus infection (CHB) Amendment 7, Part B Sub Study: The primary purpose of this amendment is to obtain preliminary data on the safety of pegylated interferon Lambda...
What is the current status of trial NCT01204762?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 197 participants. The study started on 2010-11. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01204762?
The interventions under investigation include: Entecavir (DRUG), pegIFN (DRUG), pegIFNα-2a (DRUG), PegIFN lambda (DRUG).
Who is sponsoring clinical trial NCT01204762?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.